🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

RheumatologyICD-10: M45

Find Recruiting Clinical Trials for Ankylosing Spondylitis

Search axial spondyloarthritis, nr-axSpA, and AS biologic trials — matched to your HLA-B27 status and treatment history.

🔍 Search Ankylosing Spondylitis Trials →

About Ankylosing Spondylitis

Ankylosing spondylitis (AS), now classified under axial spondyloarthritis (axSpA), is a chronic inflammatory condition primarily affecting the spine and sacroiliac joints, causing progressive stiffness, pain, and potential spinal fusion. It affects approximately 0.5–1% of the population and is strongly associated with HLA-B27 positivity. Non-radiographic axSpA (nr-axSpA) represents earlier disease without visible radiographic damage. TNF inhibitors and IL-17 inhibitors are established treatments; JAK inhibitors have more recently been approved.

What Types of Ankylosing Spondylitis Clinical Trials Exist?

axSpA/AS clinical trials test new IL-17 inhibitors, JAK inhibitors, IL-23 inhibitors (with emerging evidence), and novel small molecules. MRI-confirmed sacroiliitis, ASDAS or BASDAI activity scores, and prior NSAID and biologic failure are key eligibility determinants. Trials frequently distinguish between radiographic AS and nr-axSpA.

Find Recruiting Ankylosing Spondylitis Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Ankylosing Spondylitis Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for ankylosing spondylitis?▾
Recruiting AS/axSpA trials include IL-17A inhibitors, IL-17A/F inhibitors, JAK inhibitors, emerging IL-23 inhibitor studies, and novel oral agents. Many trials enroll both radiographic AS and nr-axSpA patients, while some focus on one subtype. NSAID failure is typically required before biologic trials.
Does HLA-B27 status affect AS trial eligibility?▾
HLA-B27 positivity supports the diagnosis but is not always required for trial enrollment. The diagnosis of axSpA requires either radiographic sacroiliitis (by X-ray or MRI) or HLA-B27 positivity with active sacroiliitis on MRI. ASAS classification criteria are standard. Know your HLA-B27 status and any imaging results.
What is the difference between AS and nr-axSpA in clinical trials?▾
Radiographic AS (r-axSpA) has structural damage visible on X-ray (sacroiliitis grade ≥2 bilaterally or grade 3–4 unilaterally). Nr-axSpA has active inflammation on MRI but no X-ray damage yet. Some trials enroll both; others specifically target nr-axSpA to study earlier intervention. Disease duration and imaging findings determine which you have.

Related Conditions

Psoriatic ArthritisRheumatoid ArthritisLupus (SLE)

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.